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1. Introduction {#sec005}
===============

Colorectal cancer (CRC) ranks third and second among the most common cancers detected in men and women, respectively, with an incidence of over 1.2 million and a mortality of 608,700 in 2008\[[@pone.0188139.ref001]\]. Over the years, considerable advances have been made in the treatment of CRC. Surgical resection still remains the mainstay in the treatment of patients with non-metastatic disease, but unfortunately, curative resection may not be possible at the time of diagnosis in most cases \[[@pone.0188139.ref002]\]. Therefore, the five-year survival rate for metastatic CRC remains poor\[[@pone.0188139.ref003]\]. Furthermore, there is still a lack of clarity regarding the optimal treatment for advanced CRC, the prognostic value of treatment, and effective prognostic markers.

Several screening modalities are currently available for colorectal cancer, including stool examination, colonoscopy, and computed tomography (CT). Many of these methods are invasive or have limited sensitivity and do not offer much value in prognostic evaluation. Nevertheless, the detection of cancer markers is a non-invasive method in the diagnosis of cancers. It is easily accepted by patients and is a simple procedure \[[@pone.0188139.ref004]\]. In clinical practice, tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19--9 are often used for the detection of adenocarcinomas \[[@pone.0188139.ref003],[@pone.0188139.ref005],[@pone.0188139.ref006]\]. Generally, serum CEA levels are elevated in the case of cancer recurrence, and therefore, this parameter is widely considered a marker for postoperative surveillance in CRC \[[@pone.0188139.ref007]--[@pone.0188139.ref009]\]. Although the specificity of CA 19--9 for detecting colorectal cancer is 96% \[[@pone.0188139.ref010]\], its sensitivity is only 23%, and its utility in predicting prognosis remains controversial \[[@pone.0188139.ref011]\]. In other words, elevated CA 19--9 levels have been reported to be strongly associated with poor prognosis in nodal-positive CRC after completion of adjuvant chemotherapy\[[@pone.0188139.ref012],[@pone.0188139.ref013]\]. However, this method is not useful in predicting the prognosis in cases of nodal-negative CRC.

To date, there has been no systematic meta-analysis on the relationship between pretreatment serum CA 19--9 levels and the prognosis in patients with CRC. We aimed to overcome this gap in knowledge through this meta-analysis.

2. Methods {#sec006}
==========

2.1. Search strategies {#sec007}
----------------------

We conducted a systematic search of various databases, such as PubMed, EMBASE and Web of Science using the following search terms: "CRC," "colorectal cancer," "colorectal tumor," "colorectal neoplasms," "colon cancer," or "rectal cancer;" and "survival," "prognostic," "prognosis," or "outcome;" and "CA 19--9 antigen," "gastrointestinal cancer antigen," "CA 19--9," or "carbohydrate antigen 19--9." All entries meeting these criteria were manually retrieved.

2.2. Inclusion and exclusion criteria {#sec008}
-------------------------------------

Two investigators independently selected articles according to inclusion criteria. Disagreements were discussed with a third reviewer. Articles meeting the following criteria were included in the meta-analysis: (1) the diagnosis of CRC was confirmed by pathological examination; (2) data on OS, DFS, PFS, and/or RFS were provided to allow for the assessment of the relationship between serum CA19-9 levels before treatment and prognosis; (3) hazard ratio (HR) and 95% confidence interval (CI) values were directly provided or could be calculated. We excluded animal studies, editorials, reviews, comments, abstracts, meetings, or case reports.

2.3. Data extraction {#sec009}
--------------------

The following data were extracted from the included studies: (1) study characteristics including the first author, country of origin, year of publication, number of patients, duration of follow-up, and method of survival analysis; (2) patient characteristics including geographical area, tumor site, age, gender, metastasis, treatment and cut-off value; (3) survival measures including HRs of OS, DFS, RFS, PFS and their 95% CIs. The HRs were extracted from multivariate or univariate analyses or estimated from Kaplan--Meier survival curves \[[@pone.0188139.ref014]\]. E-mails were also sent to the corresponding author to requesting the requested data.

2.4. Quality assessment {#sec010}
-----------------------

The quality of each study was assessed using the Newcastle--Ottawa Scale (NOS) \[[@pone.0188139.ref015]\]. If the score was more than 6, the study was considered to be of high quality.

2.5. Statistical analysis {#sec011}
-------------------------

From the data provided in each study, the HRs and their 95% CIs were calculated to assess the relationship between prognosis and pretreatment serum CA19-9 levels. We applied the random-effects model (DerSimonian--Laird method) in case of significant heterogeneity (*I*^*2*^≥50% and *P*\<0.1) and the fixed-effects model (Mantel--Haenszel method) in the absence of heterogeneity. Data analysis was conducted using the Stata 12 Edition (Stata, College Station, TX, USA). Subgroup analysis was used to evaluate the data pertaining to geographical area, distant metastasis, the type of analysis, source of HRs, sample size, and the treatment method.

3. Results {#sec012}
==========

3.1. Search result {#sec013}
------------------

The systematic database search retrieved 537 articles. Each of these extracted articles was read, and 520 articles that did not meet the inclusion criteria were excluded from further analysis ([Fig 1](#pone.0188139.g001){ref-type="fig"}). Thus, 17 studies \[[@pone.0188139.ref011],[@pone.0188139.ref016]--[@pone.0188139.ref031]\] comprising 6434 CRC patients were included in this meta-analysis, in order to assess the pretreatment levels of serum CA 19--9 as a prognostic biomarker in CRC.

![Flow diagram of the study selection process.](pone.0188139.g001){#pone.0188139.g001}

The main characteristics of all 17 studies are summarized in [Table 1](#pone.0188139.t001){ref-type="table"}. Fifteen of these studies provided data on the relationship between OS and pretreatment serum CA 19--9 levels. Five and two of these studies analyzed the relationship of pretreatment serum CA 19--9 level with DFS and with RFS and PFS, respectively. Among all 17 eligible articles, six studies were from China, six cohorts were from Japan, four studies were from the Korea, one study each was from Turkey and Czech Republic. HRs were recorded from the univariate analysis in four studies, determined from the multivariate analysis in 13 studies, and extracted from survival curves in two studies.

10.1371/journal.pone.0188139.t001

###### Main characteristics of all studies included in the meta-analysis.

![](pone.0188139.t001){#pone.0188139.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                Country/Year   Area      Tumor site                  Case number   Age (years)           Gender (M/F)   Metastasis   Treatment      Follow-up (months)   Survival analysis   Cut-off value   Analysis   HR
  --------------------- -------------- --------- --------------------------- ------------- --------------------- -------------- ------------ -------------- -------------------- ------------------- --------------- ---------- --------
  Sookyung Lee          Korea\         Eastern   Colon/rectum\               120           82/38 (\<65/≥\        59/61          No/yes\      Mixed          median\              OS                  27              UV         report
                        /2016                    88/32                                     65)                                  45/75                       7.6                                                                 

  Anna Song             Korea\         Eastern   Colon/rectum\               177           123/54 (\<65/≥\       83/94          No/yes\      Mixed          median\              OS                  27              UV         report
                        /2015                    125/52                                    65)                                  69/108                      8.3                                                                 

  Mitsuru Ishizuka      Japan/2016     Eastern   Colon/rectum\               627           169/458 (≤60/\>60)    400/227        No/yes\      surgery        median 29.9          OS                  9.5             MV         report
                                                 418/209                                                                        491/136                                                                                         

  Yuchen Wu             China/2016     Eastern   Colon/rectum\               55            28/27\                35/20          No/yes\      Mixed          NR                   OS/PFS              37              NR         report
                                                 25/30                                     (\<60/≥60)                           0/55                                                                                            

  Yukiya Narita         Japan/2014     Eastern   Colon/rectum\               252           Median\               155/97         No/yes\      chemotherapy   median 36.7          OS                  37              MV         report
                                                 148/104                                   61                                   0/252                                                                                           

  Jingtao Wang          China/2015     Eastern   Colon/rectum\               310           138/172 (\<65/≥\      152/158        No/yes\      surgery        median 71            OS/DFS              35              MV         report
                                                 176/134                                   65)                                  310/0                                                                                           

  Masatsune Shibutani   Japan/2015     Eastern   Colon/rectum\               254           median 66             139/115        No/yes\      surgery        median 1             OS                  37              UV         report
                                                 131/123                                                                        254/0                                                                                           

  Ondrej Fiala          Czech/2015     Western   Colon/rectum\               152           median 61.1           104/48         No/yes\      Mixed          median 18.9          OS/PFS              28              MV         report
                                                 86/66                                                                          0/152                                                                                           

  Tsuyoshi Ozawa        Japan/2016     Eastern   Colon/rectum\               173           mean 61               98/75          No/yes\      surgery        median 36.9          OS/RFS              37              MV         report
                                                 96/77                                                                          0/173                                                                                           

  Xian-Hua Gao          China/2013     Eastern   Colon/rectum\               742           mean 60               423/319        No/yes\      surgery        median 56            OS/DFS              37              MV         report
                                                 217/206                                                                        687/55                                                                                          

  Z.-M Li               China/2016     Eastern   Colon/rectum\               110           mean 62.9             58/52          No/yes\      surgery        median 10.4          OS                  37              MV         report
                                                 110/0                                                                          0/110                                                                                           

  Ruixue Yuan           China/2013     Eastern   Colon/rectum/unspecified\   371           mean 58.4             207/164        No/yes\      surgery        mean\                OS/DFS              37.5            MV         report
                                                 184/182/5\                                                                     341/30                      45.3                                                                

  Fatih Selcukbiricik   Turkey/2013    Western   Colon/rectum\               215           125/90 (≤60/\>60)     133/82         No/yes\      chemotherapy   median 30.8          OS                  37              MV         report
                                                 127/88                                                                         94/121                                                                                          

  HARUNOBU SATO         Japan/2011     Eastern   Colon/rectum\               1476          179/1296 (≤50/\>50)   881/595        No/yes\      surgery        median\              OS                  37              MV         report
                                                 1476/0                                                                         1476/0                      Re/NRe\                                                             
                                                                                                                                                            52.5/101.5                                                          

  Shinya Abe            Japan/2016     Eastern   Colon/rectum\               129           60/69\                80/49          No/yes\      surgery        median\              OS/RFS              50              MV         SC
                                                 67/62                                     (\<60/≥60)                           0/129                       33.6\                                                               

  IN JA PARK            Korea\         Eastern   Colon/rectum\               1109          NR                    614/501        No/yes\      surgery        median\              DFS                 37              MV         SC
                        /2009                    534/575                                                                        1109/0                      48                                                                  

  Injae Hong            Korea\         Eastern   Colon/rectum\               162           88/74 (≤62/\>62)      90/72          No/yes\      surgery        Mean\                DFS                 37              MV         report
                        /2015                    88/74                                                                          146/16                      83                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: OS overall survival, DFS disease-free survival, PFS progression-free survival, RFS relapse-free survival, HR hazard ratio, NR not report, MV Multivariate analysis, UV univariate analysis, SC survival curve.

3.2. Meta-analysis {#sec014}
------------------

### 3.2.1. Overall survival {#sec015}

Data collected from 15 studies involving 5163 patients with CRC were investigated to determine the association between pretreatment serum CA 19--9 level and OS. High pretreatment serum CA 19--9 levels were found to be associated with poor prognosis and low OS (HR: 1.58, 95% CI: 1.36--1.83, P\<0.001), and there was no significant heterogeneity between these studies (*P* = 0.179, *I*^*2*^ = 24.9%; [Fig 2](#pone.0188139.g002){ref-type="fig"}).

![Forest plots of studies evaluating hazard ratios of pretreatment serum carbohydrate antigen 19--9 level (CA199) in patients with colorectal cancer (CRC).\
(1) Pretreatment serum CA199 level was associated with shorter overall survival (OS) in CRC; (2) Pretreatment serum CA199 level was associated with shorter disease-free survival, progression-free survival, recurrence-free survival in CRC.](pone.0188139.g002){#pone.0188139.g002}

### 3.2.2. Disease-free survival {#sec016}

Data on DFS were provided by five studies involving 2694 patients. The data indicated an association between high pretreatment serum CA 19--9 levels and poor DFS (HR: 1.71, 95% CI: 1.38--2.13, *P*\<0.001), and there was no heterogeneity between studies (*P* = 0.330, *I*^*2*^ = 13.1%; [Fig 2](#pone.0188139.g002){ref-type="fig"}).

### 3.2.3. Progression-free survival and recurrence-free survival {#sec017}

Overall, data on PFS were available for 207 patients and showed that elevated pretreatment levels of serum CA 19--9 were associated with poor prognosis (HR: 1.30,95%CI:0.93--1.82, *P* = 0.121), we have got the same conclusion in RFS with 302 CRC patients (HR: 1.43, 95% CI: 1.11--1.83, *P* = 0.006). Subgroup analysis was not performed in view of the small number of RFS and PFS.

### 3.2.4. Subgroup analysis {#sec018}

Subgroup analysis was used to evaluate the data pertaining to geographical area, distant metastasis, the type of analysis, source of HRs, sample size, and the treatment method. Heterogeneity occurred in the area subgroup and the data do not account for the small sample size. There was no significant difference between the rest subgroups ([Table 2](#pone.0188139.t002){ref-type="table"}).

10.1371/journal.pone.0188139.t002

###### Pooled hazard ratios (HRs) for OS according to subgroup analyses.

![](pone.0188139.t002){#pone.0188139.t002g}

  Variables                                                         Outcome   Studies   Patients   HR (95% CI)          *P* value   Model    Heterogeneity   
  ----------------------------------------------------------------- --------- --------- ---------- -------------------- ----------- -------- --------------- -------
  **All**                                                           OS        15        5163       1.58(1.36, 1.83)     \<0.001     fixed    24.9%           0.179
                                                                    DFS       5         2694       1.71(1.38, 2.13)     \<0.001     fixed    13.1%           0.330
  **Area**                                                                                                                                                   
  Eastern                                                           OS        13        4796       1.63 (1.42, 1.87)    \<0.001     fixed    0.0%            0.579
                                                                    DFS       5         2694       1.71(1.38, 2.13)     \<0.001     fixed    13.1%           0.330
  Western                                                           OS        2         367        1.23(0.38, 4.03)     0.773       random   87.1%           0.005
                                                                    DFS       0         0          \-                   \-          \-       \-              \-
  **Analysis type**[^**\***^](#t002fn002){ref-type="table-fn"}                                                                                               
  Univariate                                                        OS        4         606        1.50(1.15, 1.95)     \<0.001     fixed    0.0%            0.865
  Multivariate                                                      OS        11        4557       1.58(1.30, 1.93)     \<0.001     fixed    43.3%           0.062
                                                                    DFS       5         2694       1.71(1.38, 2.13)     \<0.001     fixed    13.1%           0.330
  **Metastasis**[^**\***^](#t002fn002){ref-type="table-fn"}                                                                                                  
  Mixed                                                             OS        11        2871       1.51(1.25, 1.83)     \<0.001     fixed    34.9%           0.119
                                                                    DFS       3         1275       1.70(1.27,2.26)      0.004       fixed    36.2%           0.209
  No                                                                OS        4         2292       1.80(1.42, 2.28)     \<0.001     fixed    0.0%            0.608
                                                                    DFS       2         1419       1.63 (1.06, 2.51)    0.026       fixed    31.2%           0.228
  **HR obtain method**                                                                                                                                       
  Reported in text                                                  OS        14        5034       1.53(1.32, 1.77)     \<0.001     fixed    16.0%           0.279
                                                                    DFS       4         1585       1.63(1.25, 2.12)     0.001       fixed    6.5%            0.370
  Data-extrapolated                                                 OS        1         129        2.41(1.50,3.86)      \-          \-       \-              \-
                                                                    DFS       1         1109       1.84(1.40,2.44)      \-          \-       \-              \-
  **Sample size**[^**\***^](#t002fn002){ref-type="table-fn"}                                                                                                 
  \>200                                                             OS        8         4247       1.46(1.16,1.84)      \<0.001     fixed    39.9%           0.113
                                                                    DFS       4         2532       1.66(1.36,2.02)      \<0.001     fixed    0.0%            0.622
  \<200                                                             OS        7         916        1.69(1.39,2.04)      \<0.001     fixed    5.9%            0.382
                                                                    DFS       1         162        3.699(1.486,9.209)   \-          \-       \-              \-
  **Treatment method**[^**\***^](#t002fn002){ref-type="table-fn"}                                                                                            
  operate                                                           OS        9         3300       1.66(1.40,1.96)      \<0.001     fixed    2.3%            0.413
                                                                    DFS       5         2694       1.71(1.38, 2.13)     \<0.001     fixed    13.1%           0.330
  mixed                                                             OS        6         1863       1.57(1.28,1.94)      \<0.001     random   52.8%           0.048

Abbreviation: OS overall survival, DFS disease-free survival, PFS progression-free survival, RFS relapse-free survival, HR hazard ratio, CI confidence intervals.

\*indicates that the difference was statistically significant

3.3. Sensitivity analyses {#sec019}
-------------------------

We did sensitivity analysis only for OS. We removed each of the articles to assess the impact of the individual data of each of these studies on the results of this study and found no significant change in the combinations of HRs and 95% CIs. This finding reflected the stability of the outcome ([Fig 3](#pone.0188139.g003){ref-type="fig"}).

![Sensitivity analyses for confirming robustness of OS by removing 1 study each time.](pone.0188139.g003){#pone.0188139.g003}

3.4. Publication bias {#sec020}
---------------------

The publication bias in each of the included studies was calculated only for OS by funnel plots as well as Egger's and Begg's tests. The funnel plots were almost symmetrical ([Fig 4](#pone.0188139.g004){ref-type="fig"}). Furthermore, Egger's and Begg's test results revealed no significant publication bias in our study (OS: *P* = 0.347, 0.373).

![Funnel plots for the evaluation of potential publication bias of OS for CRC.](pone.0188139.g004){#pone.0188139.g004}

4. Discussion {#sec021}
=============

In this meta-analysis, we investigated the relationship between the pretreatment serum CA 19--9 levels and prognosis in 17 studies comprising 6434 patients with CRC. Our final results indicate a significant correlation between elevated pretreatment serum CA 19--9 levels and poor prognosis in CRC patients, with a combined HR of 1.58 (95% CI: 1.36--1.83, *P*\<0.001), for OS, 1.71 (95% CI: 1.38--2.13, *P*\<0.001for DFS, 1.30 (95% CI: 0.93--1.82) for RFS and 1.43 (95% CI: 1.11--1.83) for PFS. Furthermore, subgroup analyses were conducted according to the tumor site, occurrence of distant metastasis, type of analysis, method of calculating HR, sample size, and treatment. The results of analyses with all these subgroups revealed that a high pretreatment serum CA 19--9 level indicates poor prognosis, and further indicated that there was no significant difference among these different subgroups.

Although several studies have attested to the association between pretreatment serum CA 19--9 levels and the prognosis of CRC, the underlying reasons continue to remain elusive. CA 19--9 has been used in the diagnosis and prognosis of pancreatic cancer, CRC, gastric cancer, and other gastrointestinal tumors \[[@pone.0188139.ref032]--[@pone.0188139.ref034]\]. In CRC patients, the role of CA 19--9 remains controversial since it has a lower sensitivity as compared to CEA\[[@pone.0188139.ref035]\]. In the body, CA19-9 has been found to occur in salivary mucin and is distributed across the normal pancreas, gallbladder, liver, intestine, bile duct epithelium, etc. It is a cell surface glycoprotein and is involved in cellular adhesion, cancer cells expressing this protein may have greater metastatic and invasive potential \[[@pone.0188139.ref027]\]. Additionally, it has been reported to mediate the adhesion of tumor cells to the endothelial cells of blood vessels, thereby contributing to tumor metastasis \[[@pone.0188139.ref036]\]. Moreover, the presence of CA 19--9 correlate with the occurrence of tumor cell-induced platelet aggregation, which is an important process involved in the distant metastasis of CRC \[[@pone.0188139.ref037]\]. Furthermore, the possible involvement of CA 19--9 in tumor recurrence and survival may be attributed to differences in chemotherapy resistance or biological features of stage IV CRC, compared to other stages \[[@pone.0188139.ref017]\]. Such as it is reported that the baseline CA 19--9 level was an independent prognostic factor in metastatic CRC and also a predictive factor of bevacizumab efficacy, and the baseline CA 19--9 level correlated with the KRAS/BRAF mutation status \[[@pone.0188139.ref027]\]. This is also reported in another research \[[@pone.0188139.ref029]\]. CA 19--9 has also been reported to play a role in the occurrence of cancer invasion by enhancing cell adhesion and indirectly promoting angiogenesis \[[@pone.0188139.ref038]\]. Put together, these explanations, at least partly, explain the negative correlation of pretreatment serum CA 19--9 levels and prognosis.

This study has some limitations. First, our sample size was relatively small. Second, owing to the diversity of the cut-off values defined in each of these studies, we could not perform further subgroup analysis. Third, these included studies were heterogeneous due to differences in design, which also did not allow for the assessment of other clinical features.

5. Conclusion {#sec022}
=============

Thus, our meta-analysis revealed an association between high pre-treatment serum CA 19--9 levels and poor survival in patients with CRC. Hence, serum CA 19--9 levels may be used as a marker to facilitate the treatment planning and prognostic evaluation of CRC patients. As a common tumor marker today, it has the advantage that it is cheaper, more convenient and more acceptable to patients. Further investigations are necessary to determine whether any association exists between serum CA 19--9 levels and survival.
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